Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Jun;45(6):1911-4.
doi: 10.1128/AAC.45.6.1911-1914.2001.

Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae

D C Richardson  1 , D Bast, A McGeer, D E Low
Affiliations

Evaluation of susceptibility testing to detect fluoroquinolone resistance mechanisms in Streptococcus pneumoniae

D C Richardson et al. Antimicrob Agents Chemother. 2001 Jun.

Abstract

To determine if susceptibility testing of Streptococcus pneumoniae could detect those isolates that had one of the recognized mechanisms of fluoroquinolone resistance, 101 isolates were selected; the levofloxacin MIC for 28 of these isolates was > or =4 microg/ml. Only isolates with both parC and gyrA mutations or with no recognized resistance mechanisms were reliably identified by using these results. Isolates with only a parC mutation could not be detected reliably using any susceptibility testing method.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Scattergram showing correlations among levofloxacin (A) and ciprofloxacin (B) MICs and zone diameters around 5-μg disks. Numbers are the datum points at each location (101 isolates tested).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bast D J, Low D E, Duncan C L, Kilburn L, Mandell L A, Davidson R J, de Azavedo J C. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob Agents Chemother. 2000;44:3049–3054. - PMC - PubMed
    1. Brenwald N P, Gill M J, Wise R. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 1998;42:2032–2035. - PMC - PubMed
    1. Chen D, McGeer A, de Azavedo J C, Low D E The Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 1999;341:233–239. - PubMed
    1. Fournier B, Zhao X, Lu T, Drlica K, Hooper D C. Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis. Antimicrob Agents Chemother. 2000;44:2160–2165. - PMC - PubMed
    1. Frisch A W, Tripp J W, Barrett C D, Pidgeon B E. The specific polysaccharide content of pneumonic lungs. J Exp Med. 1942;76:505–510. - PMC - PubMed

Publication types

LinkOut - more resources